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ABSTRACT 
Introduction: Hypovitaminosis D is reported to be associated with several medical complica-
tions. Recent studies have reported a high worldwide prevalence of Vitamin D deficiency in 
the general population (up to 80 %). This is even higher in patients with chronic kidney dis-
ease (CKD) and increases with advancing stages of CKD. 
Objectives: To determine the difference in serum Vitamin D [25-hydroxyvitamin D, 25(OH) 
D] levels between CKD patients and normal healthy population.  
Materials and Methods: A prospective cross-sectional study involving 50 normal volunteers 
(control) and 50 patients with CKD stages 2-4. Their demographic profiles were recorded and 
blood samples taken for serum 25(OH) D, intact parathyroid hormone (iPTH) and other rou-
tine blood tests. 
Results: All subjects regardless of renal status had hypovitaminosis D (< 30ng/mL). The 
mean serum 25(OH) D were comparable in the control and CKD groups (15.3 ± 4.2 ng/mL vs 
16.1 ± 6.2 ng/mL, p = NS). However, within the Vitamin D deficient group, the CKD group 
had lower levels of serum 25(OH) D [12.6(3.7) ng/mL vs 11.2(6.5) ng/mL, p = 0.039]. Fe-
male gender [OR 22.553; CI 95 % (2.16-235.48); p = 0.009] and diabetic status [OR 6.456; 
CI 95 % (1.144-36.433); p = 0.035] were independent predictors for 25(OH) D deficiency.  
Conclusions: Vitamin D insufficiency and vitamin D deficiency are indeed prevalent and un-
der-recognized. Although the vitamin D levels among the study subjects and their control are 
equally low, the CKD group had severe degree of vitamin D deficiency. Diabetic status and 
female gender were independent predictors of low serum 25(OH)D.  
 
Keywords: 25-hydroxyvitamin D, vitamin D insufficiency and deficiency, normal population, 
CKD patients 
 
 
INTRODUCTION 
Vitamin D has been proven to modulate 
the immune system through the stimulation 
of expression of anti-microbial peptides 
(AMPs) are integral in defense mechanism 
(Schwalfenberg, 2011). Several studies 
have shown that hypovitaminosis D to be 
associated with respiratory tract infections 
including TB ((Laaksi et al., 2007; 
Nnoaham and Clarke, 2008). Vitamin D has 
been shown to be important in maintaining 
B cell homeostasis therefore may be useful 
in the treatment of B cell-mediated auto-
immune disorders (Chen et al., 2007). 
Hypovitaminosis D is associated with an 
increased risk of cardiovascular disease as 
shown by the Framingham study (Wang et 
EXCLI Journal 2013;12:511-520 – ISSN 1611-2156 
Received: March 07, 2013, accepted: May 16, 2013, published: June 11, 2013 
 
 
512 
al., 2008). It increases the risk of myocardi-
al infarction independent of diabetes, hy-
pertension and dyslipidaemia and other 
known cardiovascular risk factors (Giovan-
nucci et al., 2008). Vitamin D is proven to 
prevent nephrosclerosis and retard CKD 
progression through its anti inflammatory 
and anti proliferative properties and inhibi-
tion of renin production (Danescu et al., 
2009). In patients with established CKD, 
treatment with calcitriol was associated 
with a trend towards a lower incidence of 
dialysis initiation and a decrease in overall 
mortality rates (Autier and Gandini, 2007; 
Doorenbos et al., 2009). Interestingly, vit-
amin D also has anti cancer properties by 
promoting cell differentiation and inhibiting 
cell proliferation and angiogenesis (Gio-
vannucci et al., 2005). Studies have shown 
patients with low levels of vitamin D to be 
associated with increased cancer incidence 
(Giovannucci, 2006). 
Recent studies worldwide have report-
ed a high prevalence of vitamin D defi-
ciency in the general population and is 
even more common in patients with chronic 
kidney disease (CKD) (Zadshir et al., 2005; 
Adams and Hewison, 2010). Apart from a 
reduction in renal 1α-hydroxylase activity, 
diabetes and proteinuria have also been im-
plicated with vitamin D deficiency in CKD 
patients (Schiavi and Kumar, 2004; Holden 
et al., 2010). Interestingly, urinary protein 
losses were reported to be a more im-
portant predictor of vitamin D deficiency 
than the degree of CKD (Mehrotra et al., 
2008). 
There is poor consensus as to what con-
stitutes the optimal level of vitamin D or 
what defines vitamin D insufficiency or de-
ficiency. At present, most experts define 
vitamin D insufficiency as a 25(OH) D lev-
el of less than 30 ng/mL and levels less than 
15 ng/ml as vitamin D deficiency (Zadshir 
et al., 2005; Holick, 2006, 2007; Prentice, 
2008). With these definitions, it has been 
estimated that one billion people worldwide 
have either vitamin D deficiency or insuffi-
ciency (Lips et al., 2006). It was reported 
that among 15,390 adults in the United 
State, half had vitamin D deficiency 
(Zadshir et al., 2005). The prevalence of 
this condition increases with advancing age 
and is more predominant in Hispanics and 
Blacks compared to their white counter-
parts (Zadshir et al., 2005; Tareen et al., 
2005; Yetley, 2008). A study in post-
menopausal Asian women reported, ap-
proximately 50 % of Siamese and Malaysi-
an women had serum 25(OH)D of less than 
30ng/mL and increased to 90 % in Japanese 
and Korean women (Lim et al., 2008). 
Among the affected Malaysian, it was 
more prevalent in the Malay race compared 
to other races (Rahman et al., 2004). 
Although failure of 1,25(OH)2D3 syn-
thesis is the cause of vitamin D deficien-
cy in patients with CKD, studies on vitamin 
D levels are still based on measurements of 
serum 25(OH)D (Zittermann, 2003; Al-Badr 
and Martin, 2008). This is because the for-
mer is difficult to measure given that it‘s 
half-life is only 4-6 hours. Compared to 
25(OH)D in which is the most stable 
and plentiful metabolite of vitamin D in 
humans and has a half-life of about 3 
weeks, making it the most suitable indica-
tor of vitamin D status (Thacher and 
Clarke, 2011). Furthermore, 1,25 (OH)2D3 
circulates at picogram concentrations that 
are 1000 times less than those of the pre-
cursor 25(OH)D. Hence this metabolite 
must be extensively purified before being 
measured by radioimmunoassay (Thacher 
and Clarke, 2011). Therefore, earlier stages 
of vitamin D deficiency can be missed by 
measuring 1, 25(OH)2D3. Studies have found 
that circulating concentrations of 25(OH)D 
levels is a sensitive measurement of vitamin 
D status that reflects both intake and endog-
enous production in response to solar ultra-
violet B exposure (Jones et al., 2007; Holick, 
2007). 
In view of the association of hypovita-
minosis D with diseases and its implica-
tions, we decided to embark on this study to 
see the prevalence of hypovitaminosis D in 
our population. 
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MATERIALS AND METHODS 
A cross-sectional study comparing pa-
tients with CKD (attending follow-up at 
the Nephrology Clinic at our institution) 
with the normal healthy population. The 
study was approved by the Research and 
Ethics Committee with Research Grant FF-
227-2010. We included CKD stages 2-4 and 
aged 18 to 65 years old. Our exclusion crite-
ria included: acute renal failure, end stage 
renal disease, chronic liver disease, malab-
sorption syndromes, granulomatous disease 
and patients who were on medications 
known to affect vitamin D absorption or 
metabolism such as anticonvulsants, isonia-
zid, rifampicin, theophylline, glucocorti-
coids, calcium and vitamin D supplements. 
The control group were volunteers from our 
institution and with no medical illness.  
Estimated Glomerular Filtration Rate 
(eGFR) was calculated with the equation of 
the Modification of Diet in Renal Disease 
(MDRD) Study Group and categorized 
based on the NKF Kidney Disease Out-
comes Quality Initiative guidelines 
(K/DOQI guidelines, 2003).  
Clinical data of the control were ob-
tained by patient interview. Weight and 
height were measured to calculate BMI and 
categorized based on the Malaysian Clinical 
Practice Guideline on Management of Obe-
sity to: underweight (< 18.5 kg/m2), nor-
mal (18.5 to 22.9 kg/m2), overweight (23.0 
to 27.4 kg/m2) and obese (27.4 kg/m2) 
(Academy of Medicine of Malaysia Minis-
try of Health, 2004). Current smokers were 
defined as patients smoking at least one cig-
arette per day during the previous 6 months.  
10 ml of fasting venous blood was col-
lected for measurement of 25-hydroxy-
vitamin D (25(OH) D, intact parathyroid 
hormone (iPTH) and other routine blood 
tests. Urine was collected for urine dip-
stick, microscopy and urine protein creati-
nine index (uPCI). 
 
25-Hydroxyvitamin D Assay 125 I RIA Kit 
Serum for 25 (OH) D assays was cen-
trifuged at 3000 rpm for 10 minutes at 
room temperature and stored at -80 °C until 
assayed. The 25(OH) D was tested in dupli-
cate, in a single laboratory and was assayed 
in a single batch to avoid inter assay varia-
tions. We used the 25(OH)D assay Radio-
immunoassay Kit (DiaSorin Stillwater, Min-
nesota, USA) which has been used in several 
other studies ((Del Valle et al., 2007; Levin 
et al., 2007; Mehrotra et al., 2008; Holden 
et al., 2010). For the purposes of analysis, 
25(OH)D concentration was categorized 
based on current Kidney Disease Out-
comes Quality Initiative guidelines 
(K/DOQI guidelines, 2003) to: 
 Optimal level (> 30 ng/mL),  
insufficient (15 - 30 ng/mL) and  
deficient (< 15 ng/mL).  
 
STATISTICAL ANALYSIS 
Data were analysed using the Statistical 
Package for Social Science (SPSS) software 
version 19. Normally distributed data were 
expressed as mean ± standard deviation 
(SD) and non-normally distributed data 
were expressed as median (IQR). For 
normally distributed data Student’s t-test or 
one-way ANOVA were used and for non-
normally distributed data, Mann-Whitney U 
or Kruskal Wallis tests were used. Categor-
ical variables were analysed using χ2 or 
Fisher‘s Exact test as appropriate. Corre-
lations were tested using Pearson or Spear-
man correlation coefficients. Multivariate 
analyses were performed using binary logistic 
regression. All statistical tests were two sid-
ed and an unadjusted p value of < 0.05 was 
considered significant. 
 
RESULTS 
One hundred subjects were enrolled - 
50 healthy controls and 50 CKD patients. 
Their baseline demographics are summa-
rized in Table 1. Subjects in the control 
group were significantly younger and pre-
dominantly female. CKD patients were 
overweight or obese compared to the con-
trols. As expected, the control group had a 
normal serum creatinine, thus higher eGFR 
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and a normal blood pressure. Majority of 
the patients (58.0 %) had CKD stage 3, fol-
lowed by fifteen (30.0 %) with CKD stage 
4 and six (12.0 %) subjects with CKD stage 
2 (Table 2). Among the CKD group, there 
was a trend towards an increasing age with 
advancing CKD stage (p = 0.068). The 
leading cause of CKD in our patient cohort 
was diabetic nephropathy in 31(62.0 %) of 
the patients followed by chronic glomerulo-
nephritis in 13 (26.0 %) patients. 
 
Serum 25(OH) D levels 
All study subjects regardless of renal 
status were found to have hypovitamino-
sis D. Their mean levels of 25(OH) D 
were comparable in the control and CKD 
groups (15.3 ± 4.2 ng/mL and 16.1 ± 6.2 
ng/mL (p = 0.453) respectively. The propor-
tion of subjects with 25(OH)D insufficiency 
and 25(OH)D deficiency were also compa-
rable in both groups. However in 25(OH)D 
deficiency group, the mean levels of 
25(OH)D was significantly lower in the 
CKD groups [11.2 (6.5) ng/mL vs 12.6 (3.7), 
p = 0.039]. The serum 25(OH) D levels were 
also not different across the different CKD 
stages (p = 0.87). A further sub-analysis was 
done to compare the serum 25(OH) D lev-
els amongst CKD patients with and with-
out diabetes mellitus. The mean serum 
25(OH) D tended to be lower in diabetic 
patients compared with those in non-
diabetics. Additionally, more of the diabetic 
CKD patients were 25(OH)D deficient 
(16/31 vs 4/19, p = 0.032). Female gender 
(p < 0.001), diabetic status (p = 0.032) and 
lower serum haemoglobin levels (p = 0.002) 
were significantly associated with hypovita-
minosis D status. Multivariate analysis 
showed female gender and diabetes were 
independent predictors for Vitamin D de-
ficiency in CKD patients (Table 3). 
 
 
 
Table 1: Demographic and clinical characteristics in the control and CKD subgroup 
Characteristic Control CKD p value 
No. of subjects 50 50  
Age (yrs) 31.5 (5.0) 53.0 (14.0) < 0.001 
Gender, n (%) 
Male 
Female 
 
12 (24.0) 
38 (76.0) 
 
29 (58.0) 
21 (42.0) 
0.001 
Race, n (%)    
Malay 
Chinese 
Indian 
47 (94.0) 
0 (0.0) 
3 (6.0) 
41 (82.0) 
7 (14.0) 
2 (4.0) 
0.018 
BMI (kg/m2) 24.6 ± 4.4 29.0 ± 5.4 < 0.001 
Serum creatinine (µmol/L) 57.0 (20.3) 161.5 (68.8) < 0.001 
eGFR (mL/min/1.73m2) 110.5 (30.8) 35.0 (24.5) < 0.001 
SBP (mmHg) 120.9 ± 9.0 135.2 ± 17.7 < 0.001 
DBP (mmHg) 72.7 ± 7.1 75.7 ± 10.7 0.062 
Vit D levels(ng/mL) 15.3 ± 4.2 16.1 ± 6.2 0.453 
Vit D levels subgroup 
Insufficient (15 -  30) 
Deficient (< 15) 
 
17.7(4.6) 
12.6 (3.7) 
 
19.5(5.9) 
11.2 (6.50) 
 
0.123 
0.039 
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Table 2: Demographic and clinical characteristics at different stages of CKD 
Characteristics  Stage 2 
CKD (n = 50) 
stage 3 
 
stage 4 P value 
No. of subjects (%) 6 (12.0) 29 (58.0) 15 (30.0)  
Age 49.5 (23.0) 52.0 (14.0) 59.0 (10.0) 0.068 
BMI (kg/ m2) 29.2 ± 6.8 29.4 ± 5.0 28.2 ± 5.8 0.781 
Serum creatinine (umol/L) 95.5 (41.3) 143.0 (48.0) 212.0 (58.0) < 0.001 
eGFR (mL/min/1.73m2) 75.5 (14.8) 39.0 (15.5) 24.0 (8.0) < 0.001 
UPCI (g/mmol craetinine) 0.03 (0.04) 0.04 (0.12) 0.09 (0.12) 0.177 
Albumin (mmol/L) 45.5 (2.3) 42.0 (6.0) 43.0 (7.0) 0.009 
Haemoglobin (g/dL) 14.4 (2.5) 13.8 (3.0) 11.5 (1.1) 0.007 
Calcium (mmol/L) 2.4 ± 0.1 2.4 ± 0.1 2.3 ± 0.1 0.037 
Phosphorus (mmol/L) 1.3 (0.3) 1.1 (0.2) 1.3 (0.1) 0.02 
Serum ALP (u/L) 67.5 (31.8) 64.0 (33.0) 82.0 (52.0) 0.836 
Serum iPTH (pmol/L) 3.4 ± 0.6 5.0 ± 2.7 8.9 ± 4.9 0.001 
Serum TG (mmol/L) 1.3 (0.9) 1.5 (1.2) 1.9 (1.5) 0.057 
Serum TC (mmol/L) 4.9 (1.6) 4.8 (1.3) 5.2 (2.6) 0.832 
Serum HDL (mmol/L) 1.5 (0.6) 1.2 (0.3) 1.0 (0.3) 0.021 
Vitamin D (ng/mL) 15.7 ± 5.3 16.5 ± 5.8 15.5 ± 7.6 0.870 
 
 
Table 3: Independent predictive factor for hypovitaminosis D in CKD patients 
Study variables Wald Odds ratio 95 % CI p value 
Sex (female) 6.778 22.53 2.160 - 235.480 0.009 
Diabetes 4.461 6.456 1.144 - 36.433 0.035 
Haemoglobin 0.227 1.158 0.633 - 2.121 0.634 
 
DISCUSSION 
All patients in both groups of our 
study cohort have hypovitaminosis D. The 
control subjects despite being younger, pre-
dominantly reproductive aged females and 
almost exclusively Malay doctors and nurs-
es of our hospital, their prevalence of hypo-
vitaminosis D was no far better than the 
CKD group. Their prevalence of vitamin D 
insufficiency (15 to 30 ng/mL) was 46 % 
and vitamin D deficiency (< 15 ng/mL) was 
54 % as opposed to 60 % with vitamin D 
insufficiency and 40 % with vitamin D defi-
ciency in the CKD group. The reported 
prevalence of hypovitaminosis D has been 
consistently and unexpectedly high in al-
most all populations studied worldwide and 
across the age spectrum. A previous local 
study in primary school children aged 7-12 
years old (n = 402) showed the prevalence 
of hypovitaminosis D(< 30 ng/ml) to be 
73 % (Khor et al., 2011). Whereas, Rahman 
et al. found in post-menopausal women 
aged 50 to 65 years the level of 25(OH) 
D to be significantly lower in the post-
menopausal Malay women compared to 
Chinese women(p < 0.05) (Rahman et al., 
2004). 
However the true serum vitamin D 
level that defines hypovitaminosis D re-
EXCLI Journal 2013;12:511-520 – ISSN 1611-2156 
Received: March 07, 2013, accepted: May 16, 2013, published: June 11, 2013 
 
 
516 
mains debatable. Most studies used a se-
rum 25(OH) D level of less than 30 ng/mL 
to define hypovitaminosis D. Nonetheless 
a recent United States guideline on dietary 
requirements for calcium and vitamin D 
suggested a serum 25(OH) D levels of at 
least 20 ng/mL should be considered as an 
adequate vitamin D level which meets 
the requirements of at least 97.5 % of 
the population (Ross et al., 2011). Using 
the same definition, the prevalence of 
hypovitaminosis D in our control and 
CKD group would be reduced to 86 % 
and 76 % respectively (p = 0.202). 
Hypovitaminosis D (< 30mg/mL) has 
been shown to be associated with increased 
risk of cardiovascular disease and its risk 
factors i.e obesity, hypertension and diabe-
tes (Martins et al., 2007). However at pre-
sent the exact cut off between increased risk 
is not clear with some studies saying less 
than 20 mg/mL and also varies with differ-
ent races (Holick, 2004). As to what the op-
timum level we need to target to confer 
benefits is not clear although levels 
> 37 mg/mL has been suggested by one 
study (Martins et al., 2007). 
Since the prevalence of hypovitaminosis 
D in both of our groups was high, it raised 
the question of what were the common sim-
ilar factors in both groups. What could be 
the trigger factors? Could it be genetic? 
Could it be dietary? The two main determi-
nants of vitamin D levels are sunlight expo-
sure and dietary intake. In general, Malay-
sian diet lacks good sources of vitamin D as 
they rarely take cereal (fortified), marga-
rine, milk or cheese regularly. However in 
assessing diet we need a validated food in-
take recall. Previous studies have used a 
single 24 hour dietary recall (Holden et al., 
2010; Mehrotra et al., 2008). However this 
method is prone to recall bias and may not 
represent an individual‘s general dietary 
intake and habits.  
Sunlight exposure between studies is al-
so non-consistent and often there is no ob-
jective measurement of sun exposure 
(Levin et al., 2007; Del Valle et al., 2007). 
The validated measures of sun exposure has 
only been published very recently (Saliba et 
al., 2012). Hypovitaminosis D of both nor-
mal and CKD subjects due to the lack of 
sun exposure is undeniably important as 
Malaysia is a tropical country with a hot 
and humid climate. Surprisingly, many oth-
er countries with a lot of sun exposure such 
as in the Middle East also showed a similar 
prevalence of hypovitaminosis D (Sedrani, 
1984; McGrath et al., 2001; Marwaha et al., 
2005). This may be explained by the fact 
that these Muslim countries require women 
to be fully covered except for the hands and 
face thus reducing their exposure to sun-
light. This finding has been supported by 
studies in European countries where the 
prevalence hypovitaminosis D is high in 
immigrants who are covered and veiled 
(Lowe et al., 2010). As our study also con-
sists of predominantly Muslim women 
(76 % in control group and 42 % in CKD 
group) who shared similar attire code as 
their counterparts worldwide, this is likely 
to play a major part in contributing to the 
reduced serum vitamin D levels from sun 
exposure. 
Race is a major contributor to hypovit-
aminosis D worldwide. The Blacks and 
Hispanics were reported to have higher 
prevalence of hypovitaminosis D com-
pared to the Caucasians (Gutiérrez et al., 
2011). South Asian women had signifi-
cantly higher serum PTH and lower se-
rum 25(OH)D concentrations than Cau-
casian women in the UK (Lowe et al., 
2010). However, this was not associated 
with higher levels of markers of bone re-
sorption or reduced bone quality in the South 
Asian women (Lowe et al., 2010). 
In the present study, female gender and 
diabetes mellitus were found to be inde-
pendently associated with lower levels of 
25(OH)D. Female gender was found to 
have an inverse relationship with serum 
25(OH)D levels in previous study (Mehro-
tra et al., 2008). This could explain the high 
prevalence of hypovitaminosis D in our 
population whereas in diabetes, there is 
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emerging data showing Vitamin D defi-
ciency to be a contributing factor for the 
development of both type 1 and 2 diabetes. 
The β cells of pancreas not only secrets in-
sulin but also contains vitamin D receptor 
(VDRs) as well as 1-α hydroxylase en-
zymes. It has been proven that treatment 
with vitamin D improves glucose tolerance 
and insulin resistance (Martin and Camp-
bell, 2011).  
BMI and obesity have also been impli-
cated with hypovitaminosis D. Obesity re-
duces the availability of vitamin D due to 
sequestration of vitamin D in body fat 
(Holick, 2007). These findings emphasize 
the need for appropriate interventions to 
address the problem of obesity in our 
younger population to reduce the risk of 
the metabolic syndrome later in life. As 
shown in our study, the control group was 
found to be overweight whereas in the CKD 
group were noted to be obese.  
In CKD, the loss of the renal1α-
hydroxylase is largely responsible for the 
hypovitaminosis D. Several epidemiologic 
studies have reported patients with CKD 
stages 3 to 5 to have lower 25(OH) D con-
centrations than the general population 
(González et al., 2004; Levin et al., 2007). 
These in keeping with our findings. The 
identification of extrarenal 1α-hydroxylase 
suggests that 25(OH)D status is an important 
consideration in patients with CKD (Gal-
Moscovici and Sprague, 2007). Ideally, the 
serum levels of 1,25 (OH)2D3 which is the 
biologically active form of Vitamin D 
should be measured. However, low levels 
of the 25(OH)D itself may contribute to 
decreased levels of 1,25(OH)2D3 produc-
tion, particularly in CKD patients with 
nephrotic range proteinuria (Levin et al., 
2007). 
There is an association between lower 
serum 25(OH)D levels and poorer kid-
ney function, higher BMI and higher 
albuminuria, lower serum calcium and 
higher serum phosphorus, intact parathyroid 
hormone (iPTH) and alkaline phosphatase 
(ALP) . Nutritional factors associated with 
higher 25(OH)D levels were stable 
weight, higher albumin and HDL choles-
terol (Holden et al., 2010). In our CKD pa-
tients, the serum levels of albumin, haemo-
globin, calcium and high density lipoprotein-
cholesterol (HDL) decreased proportionately 
with advancing CKD stage. Whereas, the 
levels of serum phosphorus, ALP and iPTH 
rose significantly. Once eGFR drops to less 
than 30 ml/min/1.73m2 (CKD stage 4), the 
1α-hydroxylase activity becomes impaired. 
This in turn will cause a significant decrease 
in intestinal calcium absorption leading to a 
reduction in circulating serum calcium. As a 
result, secondary hyperparathyroidism de-
velops which results into osteopenia, osteo-
porosis and increasing fracture risk. Parathy-
roid hormone also causes increased phospha-
turia, resulting in low-normal serum phos-
phorus. Without an adequate calcium-
phosphorus product, mineralization of the 
collagen matrix is diminished hence aggra-
vating the renal bone disease in CKD. 
In view of such a high prevalence of 
hypovitaminosis D in CKD and its possible 
complications, we have proceeded with a 
further study to see the effects of vitamin D 
replacement in this group of patient. How-
ever this is beyond the scope of this paper. 
 
CONCLUSIONS AND CLINICAL 
IMPLICATIONS 
There is enough evidence to treat pa-
tients with hypovitaminosis D and CKD. 
However the role of vitamin D replacement 
in the general healthy population remains 
debatable. Thus a larger study with longer 
follow up is required.  
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